About Adamed

About Adamed

We are a pharmaceutical and biotechnology company established on the basis of Polish scientific advances and our own patents.

 

Adamed is one of the ten largest pharmaceutical companies operating in Poland. Adamed is the leader in next-generation pharmaceuticals – we were the first Polish company to undertake research into innovative therapies back in 2001. To date, We have invested 1.5 billion Polish zloty in research and development to date, and our portfolio currently boasts around 500 products. We establish industry-academia consortia with leading universities and research institutes in Poland and abroad.

Over 30 years of innovation and 130 years of tradition

1986

Adamed was founded by Marian Adamkiewicz MD, PhD

1991

The first drug for treatingurinary tract infections is launched. The development of an original technology for producing high-grade furaginum makes treatment for urologic conditions available to millions of patients

1994

The first manufacturing facility is opened in Pieńków, near Warsaw

1998

The first Polish-made amlodipine is registered. The method of synthesising amlodipine is improved: the new production process, that was first developed in Poland, means the number of patients who can benefit from the therapy has grown significantly, from 75,000 to more than 1.5 million today

1999-2000

The Research and Development Division is established. Adamed meets the standards of good manufacturing practice established by the European Union and is awarded the GMP EU certificate

2001

Research into innovative drugs (in the areas of oncology and central nervous system diseases) is initiated

2002

A second manufacturing plant is opened in Ksawerów, near Łódź

2003

Adamed starts exporting its products

2005-2009

The first industry-academia consortium is formed with the Jagiellonian University

2010

Acquisition of Polfa Pabianice and Agropharm

2010-2012

Adamed undergoes consolidation. Establishment of a branch in Russia

2013

Establishment of a branch in Kazakhstan

2013-2014

The construction of Adamed’s state-of-the-art R&D Centre begins

2015

The Oncotrail project is launched

2016

Adamed’s state-of-the-art R&D Centre becomes operational. The company establishes branches in Slovakia and the Czech Republic

2017

Acquisition of a controlling interest in the Vietnamese pharmaceutical company Dat Vi Phu

2018

Pilot R&D Production Area (Pilot Plant) becomes operational

2019

Establishment of a branch in Italy and acquisition of a block of shares in the Italian company Ecupharma
1986
1991
1994
1998
1999-2000
2001
2002
2003
2005-2009
2010
2010-2012
2013
2013-2014
2015
2016
2017
2018
2019
 
 

Awards and honours

Original pharmaceuticals

Adamed’s work is based on two research platforms. We search for novel oncology medicines and medications to treat central nervous system disorders.

We enhance existing therapies

At Adamed, we develop medicines with an added value.

#Adamedforthefamily


Get to know the Adamed family better



Read more